Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

被引：1
|
作者：
Di Giacomo, Anna Maria
Covre, Alessia
Finotello, Francesca
Rieder, Dietmar
Sigalotti, Luca
Giannarelli, Diana
Petitprez, Florent
Lacroix, Laetitia
Cutaia, Ornella
Fazio, Carolina
Coral, Sandra
Anichini, Andrea
Bock, Christoph
Lowder, James N.
Azab, Mohammad
Fridman, Wolf-Herman
Sautes-Fridman, Catherine
Trajanoski, Zlatko
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[3] Med Univ Innsbruck, Bioctr, Div Bioinformat, Innsbruck, Austria
[4] Ctr Riferimento Oncol CRO Aviano, Oncogenet & Funct Oncogen Unit, Aviano, Italy
[5] Regina Elena Inst Canc Res, IRCSS, Rome, Italy
[6] Cordeliers Res Ctr, INSERM, UMR S 1138, Paris, France
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[9] Astex Pharmaceut, Dublin, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2549
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2549
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
    Kudchadkar, Ragini Reiney
    Gibney, Geoffrey Thomas
    Weber, Jeffrey
    Chen, Ann
    Smith, Kim
    Merek, Stephanie
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
    Maccalli, Cristina
    Giannarelli, Diana
    Capocefalo, Filippo
    Pilla, Lorenzo
    Fonsatti, Ester
    Di Giacomo, Anna Maria
    Parmiani, Giorgio
    Maio, Michele
    ONCOIMMUNOLOGY, 2016, 5 (02):
  • [23] The Italian Network for Tumor Biotherapy (NIBIT)-M1 study: 2-years survival update for metastatic melanoma patients treated with ipilimumab in combination with fotemustine
    Di Giacomo, A. M.
    Ascierto, P. A.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Giannarelli, D.
    Parmiani, G.
    Maio, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [24] Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
    Gibney, Geoffrey T.
    Hamid, Omid
    Lutzky, Jose
    Olszanski, Anthony J.
    Mitchell, Tara C.
    Gajewski, Thomas F.
    Chmielowski, Bartosz
    Hanks, Brent A.
    Zhao, Yufan
    Newton, Robert C.
    Maleski, Janet
    Leopold, Lance
    Weber, Jeffrey S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [25] Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
    Patel, Sapna Pradyuman
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Hwu, Patrick
    Radvanyi, Laszlo George
    Mahoney, Sandy
    Deburr, Tawania L.
    Liu, Ping
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study.
    Thomas, Luc
    Wolchok, Jedd D.
    Garbe, Claus
    Lebbe, Celeste
    Bondarenko, Igor
    Rodrigues, Kristen
    Konto, Cyril
    Chin, Kevin M.
    Francis, Stephen
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [28] Safety and efficacy of local irradiation in patients with metastatic melanoma treated with the CTLA-4 antibody ipilimumab
    Weder, Samantha
    Weder, Samantha
    Hottinger, Anna-Lena
    Rothschild, Sacha
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (12) : 1149 - 1149
  • [29] Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaive patients with metastatic melanoma (MM).
    Amaria, Rodabe Navroze
    Bassett, Roland L.
    Simpson, Lauren
    Delaney, Frances
    Hwu, Patrick
    Kim, Kevin
    Hwu, Wen-Jen
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Davies, Michael A.
    Woodman, Scott Eric
    Yee, Cassian
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Efficacy and Safety of Ipilimumab in Patients with Metastatic Melanoma: Summary of Results from two Ipilimumap Phase III Studies
    Schadendorf, D.
    Becker, J.
    Garbe, C.
    Hauschild, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 (09): : 778 - 779
12345